An observational study in Rheumatoid Arthritis, Arthralgia and Joint Pain, sponsored by Vastra Gotaland Region. Status unknown at 1 site in Sweden. Per ClinicalTrials.gov, last updated 2022-05-04.
Sponsored by Vastra Gotaland Region · Observational
Among 11 studies in Arthritis, Rheumatoid by Vastra Gotaland Region — 2 open to participants now, 5 under way, none of them phase 3. Arthritis, Rheumatoid · Vastra Gotaland Region.
Among the 11 studies in Arthritis, Rheumatoid by Vastra Gotaland Region, this one is the only one that started in 2013, is one of 5 observational ones, and was the 4th registered.
3,334 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →2 of the 11 studies in Arthritis, Rheumatoid by Vastra Gotaland Region are open now, in 1 country. Recruiting first, the newest first:
Vastra Gotaland Region · Sites in Sweden
Ages 18–85
Vastra Gotaland Region · Sites in Sweden
Ages 18–80 · Healthy volunteers
By country, each count listing its studies:
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 6,000 is above the median of 176 across 1,017 observational studies indexed under Arthritis, Rheumatoid.
Median enrollment 81 across the 6 interventional studies, 2,500 across the 5 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Vastra Gotaland Region is the lead sponsor of 276 studies on the registry; 110 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Arthritis, Rheumatoid by Vastra Gotaland Region, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Purpose: to examine the possibility of using the onco-protein survivin as a predictive biomarker for identifying individuals at risk of developing rheumatoid arthritis within a cohort of patients seeking treatment for joint pain/stiffness. Secondly, to study survivin as a prognostic marker for joint destruction, refractory and highly active disease in patients with established RA.
The study will analyse survivin levels in a non-selected material within a cohort of patients seeking help at their primary health care for joint pain, stiffness, swelling etc. Patients presenting with such symptoms (not explained by injury or other factors) are suspected to have an arthritic condition such as RA, and are routinely tested for presence of autoantibodies RF and ACPA. In this observational study we add measurement for survivin to the blood analyses of these patients. Information about patients expressing high levels of survivin will be reported to the referring doctor at the primary health care, and for patients not previously having been examined by a rheumatologist this will be offered.
The study will be performed at Sahlgrenska university hospital Gothenburg and Umeå university hospital.
Patients seeking treatment at the primary health care for problems with their joints (pain, stiffness).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Survivin positive
Survivin positive: \> 0,45 ng/ml Survivin negative: \< 0,45 ng/ml
Time frame: 1 year
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2013 (actual). Primary completion is estimated for Jun 2023, 120 months after the start.
Of 236 non-industry observational studies under Arthritis, Rheumatoid, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 122. This study's planned 120 months is above that.
Counting every sponsor, half of 391 studies reached it within 50 months; a quarter within 25 and three quarters within 113.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.